vs
Forafric Global PLC（AFRI）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Forafric Global PLC的1.4倍（$219.9M vs $159.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -7.5%，领先6.5%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $146.0K）
Forafric Global PLC是一家聚焦非洲市场的农业综合企业，业务覆盖农产品生产、加工、分销全价值链，主营谷物、植物油等主食产品，核心市场为北非和西非地区，服务多领域客户，助力区域粮食安全保障。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AFRI vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.4倍
$159.7M
净利率更高
OFIX
高出6.5%
-7.5%
自由现金流更多
OFIX
多$16.7M
$146.0K
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $159.7M | $219.9M |
| 净利润 | $-12.0M | $-2.2M |
| 毛利率 | 10.7% | 71.1% |
| 营业利润率 | -2.5% | 0.2% |
| 净利率 | -7.5% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFRIOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | — | $205.6M | ||
| Q2 25 | $159.7M | $203.1M | ||
| Q1 25 | — | $193.6M | ||
| Q4 24 | — | $215.7M | ||
| Q3 24 | — | $196.6M | ||
| Q2 24 | $145.6M | $198.6M | ||
| Q1 24 | — | $188.6M |
净利润AFRIOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | — | $-22.8M | ||
| Q2 25 | $-12.0M | $-14.1M | ||
| Q1 25 | — | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | $-8.6M | $-33.4M | ||
| Q1 24 | — | $-36.0M |
毛利率AFRIOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | 10.7% | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | 9.4% | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率AFRIOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | -2.5% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | -0.9% | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率AFRIOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | — | -11.1% | ||
| Q2 25 | -7.5% | -6.9% | ||
| Q1 25 | — | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | -5.9% | -16.8% | ||
| Q1 24 | — | -19.1% |
每股收益（稀释后）AFRIOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.57 | ||
| Q2 25 | — | $-0.36 | ||
| Q1 25 | — | $-1.35 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.71 | ||
| Q2 24 | — | $-0.88 | ||
| Q1 24 | — | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3M | $450.0M |
| 总资产 | $246.1M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AFRIOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | $12.2M | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | $16.4M | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务AFRIOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | $18.4M | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益AFRIOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | — | $442.5M | ||
| Q2 25 | $5.3M | $458.3M | ||
| Q1 25 | — | $458.3M | ||
| Q4 24 | — | $503.1M | ||
| Q3 24 | — | $525.9M | ||
| Q2 24 | $16.3M | $546.0M | ||
| Q1 24 | — | $570.3M |
总资产AFRIOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | — | $832.6M | ||
| Q2 25 | $246.1M | $837.2M | ||
| Q1 25 | — | $823.1M | ||
| Q4 24 | — | $893.3M | ||
| Q3 24 | — | $867.9M | ||
| Q2 24 | $287.1M | $882.0M | ||
| Q1 24 | — | $906.0M |
负债/权益比AFRIOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | 1.13× | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $706.0K | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $146.0K | $16.8M |
| 自由现金流率自由现金流/营收 | 0.1% | 7.6% |
| 资本支出强度资本支出/营收 | 0.4% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流AFRIOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | — | $12.4M | ||
| Q2 25 | $706.0K | $11.6M | ||
| Q1 25 | — | $-18.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | $10.5M | $9.0M | ||
| Q1 24 | — | $-18.6M |
自由现金流AFRIOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | $146.0K | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | $6.4M | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率AFRIOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | 0.1% | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | 4.4% | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度AFRIOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 2.8% | 4.7% | ||
| Q1 24 | — | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFRI
| Sales to external customers, Total | $159.7M | 100% |
| Couscous & Pasta | $934.0K | 1% |
| Soft Wheat | $393.0K | 0% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
